Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01382069
Other study ID # CCN010
Secondary ID HHSN275201000080
Status Completed
Phase Phase 1
First received March 25, 2011
Last updated June 29, 2017
Start date March 2012
Est. completion date May 2017

Study information

Verified date July 2016
Source Los Angeles Biomedical Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The long term objective is to develop a new male hormone Dimethandrolone Undecanoate (DMAU) as a male hormonal contraceptive.

The study has two parts. The first is a dose escalating study in healthy to assess the safety and tolerability of single dose oral administration of DMAUin healthy men.(Completed)

The second is to study the safety and tolerability of DMAU after 28 days of repeated daily dosing of DMAU in healthy men. (Currently Recruiting) In both parts the investigators will also study the pharmacokinetics of Dimethandrolone (DMA) in the serum after oral administration of DMAU.


Description:

The study will be conducted in two centers.

28-Day Repeat-Dose, Dose-Escalation Study: Based on the safety and tolerability of the single dose study and serum DMA levels attained, three doses of two formulations of DMAU were selected for a dose-escalating 28-day repeat dose study. Safety will be assessed in subjects receiving lower dosages before additional men receive higher doses for 28 days. Up to 100 men will be randomized to receive either active drug or an identical number of capsules of placebo. The 24-hour detailed PK of DMA will be assessed on day 1 and 28. Trough levels of DMA will be obtained throughout the 28-day period and at 48 and 72 hours after the last dose. In addition to safety and tolerability, suppression of serum T, gonadotropins, and SHBG will also be assessed as secondary pharmacodynamic (PD) endpoints. Psychosexual diaries for 7 consecutive days and PHQ-9 (questionnaire)will be obtained before and at the end of the study period.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date May 2017
Est. primary completion date February 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. Male volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine at the time of screening.

2. 18 to 50 years of age.

3. BMI < 33 calculated as weight in kg/ (height in m2 )

4. No history of hormonal therapy use in the last three months prior to the first screening visit.

5. Subject will agree to use a recognized effective method of contraception with his partner (i.e. at a minimum, use double-barrier contraception) during the course of the study treatment and recovery phase.

6. Subjects will refrain from donating blood or plasma during the study period.

7. Subjects will be advised to refrain/abstain from alcoholic beverages and grapefruit juice during the study period.

8. Subjects will not use cannabis or any recreational drugs at least 4 weeks before screening and during the study.

9. In the opinion of the investigator, subject is able to comply with the protocol, understand and sign an informed consent and HIPAA form.

10. Does not meet any of the exclusion criteria.

Exclusion Criteria:

1. Men participating in another clinical trial involving an investigational drug within the last 30 days prior to the first screening visit.

2. Men not living in the catchment's area of the clinic or within a reasonable distance from the study site.

3. Clinically significant abnormal physical and laboratory findings at screening.

4. Elevated PSA (levels = 2.5 ng/mL), according to local laboratory normal values.

5. Abnormal serum chemistry values, according to local laboratory reference ranges that indicate liver or kidney dysfunction or that may be considered clinically significant except for: an upper limit for fasting bilirubin is less than 2 mg/dL, upper limit for cholesterol is less than 220 mg/dL, or upper limit for fasting triglycerides is less than 200 mg/dL.

6. Abnormal semen analyses or abnormal semen concentration as defined by the WHO semen manual.

7. Use of androgens or other body building substances including nutritional supplements within 3 months before first screening visit.

8. Systolic BP > 130 mm Hg and Diastolic blood pressure BP > 80 and mm Hg; ((BP) Blood pressure will be taken 3 times at 5-minute intervals and the mean of all measurements be considered).

9. Clinically significant abnormal EKG and a QTc interval of > 450 msec.

10. PHQ-9 score of 15 or above [for the 28 days study].

11. History of hypertension, including hypertension controlled with treatment.

12. Known history of primary testicular disease or disorders of the hypothalamic-pituitary axis.

13. Benign or malignant liver tumors; active liver disease.

14. History of breast carcinoma.

15. Known history of androgen deficiency due to hypothalamic-pituitary or testicular disease.

16. Known history of cardiac, renal, hepatic or prostatic disease.

17. Positive serology for Hepatitis or HIV at screening visit.

18. A serious systemic disease such as diabetes mellitus or obesity (body weight greater than BMI >33 kg/m2 as above).

19. History of known, untreated sleep apnea.

20. Known or suspected alcoholism or drug abuse that may affect metabolism/transformation of steroid hormones and study treatment compliance.

21. Partner is known to be pregnant.

22. Men desiring fertility within the first 24 weeks of study participation.

23. Men participating in competitive sports where drug screening for prohibited substances (including anabolic steroids) is routine will be advised of the relative and temporary hazards that participating in this study may have for their fertility or sporting status.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dimethandrolone Undecanoate
Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
Placebo
Placebo with capsules that look like the DMAU capsules but with no active ingredients

Locations

Country Name City State
United States University of Washington Seattle Washington
United States Los Angeles Biomedical Research Institute Torrance California

Sponsors (3)

Lead Sponsor Collaborator
Los Angeles Biomedical Research Institute National Institutes of Health (NIH), University of Washington

Country where clinical trial is conducted

United States, 

References & Publications (3)

Attardi BJ, Engbring JA, Gropp D, Hild SA. Development of dimethandrolone 17beta-undecanoate (DMAU) as an oral male hormonal contraceptive: induction of infertility and recovery of fertility in adult male rabbits. J Androl. 2011 Sep-Oct;32(5):530-40. doi: 10.2164/jandrol.110.011817. Epub 2010 Dec 16. — View Citation

Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology. 2006 Jun;147(6):3016-26. Epub 2006 Feb 23. — View Citation

Attardi BJ, Marck BT, Matsumoto AM, Koduri S, Hild SA. Long-term effects of dimethandrolone 17ß-undecanoate and 11ß-methyl-19-nortestosterone 17ß-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats. J Androl. 2011 Mar-Apr;32(2):183-92. doi: 10.2164/jandrol.110.010371. Epub 2010 Aug 26. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men Number of severe or serious adverse event fdter escalating single doses of Dimethandrolone Undecanoated in a single dose escalating study or after 28 days repeat dosing in healthy men 1 day
Secondary Single Dose, Dose-Ranging and 28 days Repeat Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men Serum Dimethandrolone Levels on day 28 28 days
Secondary Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men Serum Dimethandrolone levels 2 days Food or no food
Secondary Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men Serum hormone levels (Testosterone (T), FSH and LH and SHBG) and sexual function. 28 DAYS
See also
  Status Clinical Trial Phase
Completed NCT02575209 - Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects N/A
Completed NCT00900107 - Time-Dependent Mobilization of Circulating Progenitor Cells During Strenuous Exercise in Healthy Individuals N/A
Completed NCT02517775 - Effects of Cranberry Consumption in Vascular Function in Healthy Individuals N/A
Active, not recruiting NCT03298373 - 28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men Phase 1
Completed NCT03339167 - Metabolic Availability of Lysine From Millet in Adult Men N/A
Completed NCT01710280 - Palmitic Acid in the Sn-2 Position of Triacylglycerols and Postprandial Lipemia N/A
Completed NCT01130948 - Sleep, Breathing and Psychomotor Performance at Altitude: A Physiologic Study in Healthy Subjects N/A
Recruiting NCT05523674 - Effects of Warm-up Intensity and Blood Flow Restriction N/A
Not yet recruiting NCT05865574 - A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection Phase 1
Completed NCT01293591 - Garlic Intake And Biomarkers Of Cancer Risk N/A
Completed NCT01296997 - Calcium Phosphate and Incretins N/A
Completed NCT01221558 - Effects of Lycopene on Oxidative Stress and Markers of Endothelial Function Healthy Men Phase 3
Completed NCT00935662 - A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses Phase 1
Active, not recruiting NCT05825781 - Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man Phase 1
Completed NCT02994602 - Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males Phase 1
Completed NCT02365987 - The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety N/A
Completed NCT02093169 - D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound Phase 1
Completed NCT02072278 - Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects Phase 1
Completed NCT03411005 - Metabolic Availability of Lysine From Sorghum in Adult Men N/A
Recruiting NCT02927210 - Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015) Phase 1